Article
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2015
de la Rochefordiere Anne, Kamal Maud, Floquet Anne, Thomas Laurence, Petrow Peter, Petit Thierry, Pop Marius, Fabbro Michel, Kerr Christine, Joly Florence, Sevin Emmanuel, Maillard Sophie, Curé Hervé, Weber Béatrice, Brunaud Claire, Minsat Mathieu, Gonzague Laurence, Berton-Rigaud Dominique, Aumont Maud, Gladieff Laurence, Peignaux Karine, Bernard Virginie, Leroy Quentin, Bieche Ivan, Margogne Audrey, Nadan AnaTereza, Fourchotte Virginie, Diallo Alhassane, Asselain Benard, Plancher Corine, Armanet Sébastien, Beuzeboc Philippe, Scholl Suzy M
Abstract excerpt
PURPOSE: EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used conjointly with radiochemotherapy, was feasible in first-line treatment of cervix carcinoma limited to the pelvis. EXPERIMENTAL DESIGN: This randomized phase II trial enrolled 78 FIGO stage IB2-IIIB cervical cancer patients to either cisplatin-based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.